Candel Therapeutics (CADL) EBIT (2020 - 2025)
Candel Therapeutics (CADL) posted EBIT of -$15.8 million for Q4 2025, down 19.27% sequentially from -$13.2 million in Q3 2025, and down 93.49% YoY from -$242.0 million in Q4 2024.
Candel Therapeutics (CADL) EBIT (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported EBIT for 6 years, with the latest figure at -$15.8 million in Q4 2025.
- Quarterly EBIT fell 93.49% year-over-year to -$15.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$48.3 million (down 44.63% YoY) and the FY2025 annual result came in at -$48.3 million, down 44.63% from the prior year.
- EBIT retreated to -$15.8 million in Q4 2025 per CADL's latest filing, from -$13.2 million in the prior quarter.
- Over five years, EBIT peaked at -$4.7 million in Q1 2021 and troughed at -$15.8 million in Q4 2025.
- A 5-year average of -$9.0 million and a median of -$8.8 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2021 and 2024: EBIT plunged 192.07% in 2021, then grew 21.1% in 2024.
- Over 5 years, EBIT stood at -$7.7 million in 2021, then fell by 4.66% to -$8.1 million in 2022, then slipped by 27.37% to -$10.3 million in 2023, then rose by 21.1% to -$8.1 million in 2024, then tumbled by 93.49% to -$15.8 million in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$15.8 million, -$13.2 million, and -$11.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -15.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.75 Mn |
| Sep 30, 2025 | -13.21 Mn |
| Jun 30, 2025 | -11.18 Mn |
| Mar 31, 2025 | -8.13 Mn |
| Dec 31, 2024 | -8.14 Mn |
| Sep 30, 2024 | -8.76 Mn |
| Jun 30, 2024 | -8.57 Mn |
| Mar 31, 2024 | -7.90 Mn |
| Dec 31, 2023 | -10.32 Mn |
| Sep 30, 2023 | -8.86 Mn |
| Jun 30, 2023 | -9.58 Mn |
| Mar 31, 2023 | -9.63 Mn |
| Dec 31, 2022 | -8.10 Mn |
| Sep 30, 2022 | -8.88 Mn |
| Jun 30, 2022 | -8.75 Mn |
| Mar 31, 2022 | -8.99 Mn |
| Dec 31, 2021 | -7.74 Mn |
| Sep 30, 2021 | -8.03 Mn |
| Jun 30, 2021 | -5.30 Mn |
| Mar 31, 2021 | -4.66 Mn |